Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The gold rush for induced pluripotent stem cells

As the first commercial ventures are formed around induced pluripotent stem (iPS) cell research, who will have the freedom to operate commercially remains a big unknown. Sarah Webb reports.

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Ebert, A.D. et al. Nature 457, 277–281 (2009).

    CAS  Article  Google Scholar 

  2. Dimos, J.T. et al. Science 321, 1218–1221 (2008).

    CAS  Article  Google Scholar 

  3. Soldner, F. et al. Cell 136, 964–977 (2009).

    CAS  Article  Google Scholar 

  4. Lee, G. et al. Nature 461, 402–406 (2009).

    CAS  Article  Google Scholar 

  5. Kim, D. et al. Cell Stem Cell 4, 472–476 (2009).

    CAS  Article  Google Scholar 

  6. Lin, T. et al. Nature Methods, published online 18 October, 2009, doi10.1038/nmeth.1393.

  7. Yu, J. et al. Science 324, 797–801 (2009).

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Webb, S. The gold rush for induced pluripotent stem cells. Nat Biotechnol 27, 977–979 (2009). https://doi.org/10.1038/nbt1109-977

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1109-977

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing